Munster, Pamela
Krop, Ian E.
LoRusso, Patricia
Ma, Cynthia
Siegel, Barry A.
Shields, Anthony F.
Molnár, István
Wickham, Thomas J.
Reynolds, Joseph
Campbell, Karen
Hendriks, Bart S.
Adiwijaya, Bambang S.
Geretti, Elena
Moyo, Victor
Miller, Kathy D.
Funding for this research was provided by:
Merrimack Pharmaceuticals, Inc.
Article History
Received: 8 February 2018
Revised: 28 June 2018
Accepted: 27 July 2018
First Online: 26 October 2018
<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate
: The study protocol and its amendments were approved by the Independent Ethics Committees and/or Institutional Review Boards (Dana Farber Cancer Institute, Indiana University Health Melvin and Bren Simon Cancer Center, Wayne State University Department of Oncology, Karmanos Cancer Institute, University of California, San Francisco, Washington University School of Medicine). The study complied with recommendations of the 18th World Health Congress (Helsinki, 1964) and all applicable amendments. The study also complied with the laws and regulations, as well as any applicable guidelines, in the United States (the only country in which the study was conducted).
: This trial was funded by Merrimack Pharmaceuticals, Inc. Merrimack Pharmaceuticals had roles in the study design; collection, analysis, and interpretation of data; writing of the report and decision to submit paper for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
: Not applicable. There is nothing to consent.
: P.M. has nothing to declare. C.M.’s institution received financial support from Merrimack Pharmaceuticals to conduct this trial. P.L.’s former institution received financial support from Merrimack Pharmaceuticals to conduct this trial. Dr LoRusso has provided consultancy for: Agios, Alexion, Ariad, GenMab, Glenmark, Halozyme, Menarini, Novartis, Roche-Genentech, Genentech, CytomX, Omniox, and Ignyta. B.A.S. has received consulting fees from Merrimack Pharmaceuticals and his institution received financial support from Merrimack Pharmaceuticals to conduct this trial. Dr Siegel also received grants from the National Cancer Institute, and personal fees from Beacon Biosciences during the conduct of the study. AFS received consulting fees from Merrimack Pharmaceuticals and his institution received financial support from Merrimack Pharmaceuticals to conduct this trial. IM was an employee of Merrimack at the time of the study, and is a consultant for Ipsen Biosciences outside of the submitted work. J.R. was an employee of Merrimack at the time of the study. K.C. was an employee of Merrimack at the time of the study. B.S.H. was an employee of Merrimack at the time of the study. B.A. is an employee of Merrimack. E.G. was an employee of Merrimack at the time of the study. V.M. was an employee of Merrimack at the time of the study, is an equity owner in L.E.A.F. Pharmaceuticals LLC outside of the submitted work. In addition, Dr Moyo has a patent null pending. K.D.M. received financial support to her institution from Merrimack Pharmaceuticals to conduct this trial. T.J.W. was an employee of Merrimack at the time of the study.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).